Janney Capital Management LLC Trims Stake in Pfizer Inc. (NYSE:PFE)

Janney Capital Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 395,819 shares of the biopharmaceutical company's stock after selling 54,845 shares during the period. Janney Capital Management LLC's holdings in Pfizer were worth $10,501,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP raised its holdings in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter valued at $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the 3rd quarter worth $35,000. Finally, Joseph Group Capital Management increased its position in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 771 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim decreased their target price on Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Citigroup started coverage on Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 price objective for the company. Finally, Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

Pfizer Stock Down 2.4 %

PFE stock traded down $0.63 during trading on Wednesday, reaching $26.01. The stock had a trading volume of 41,814,820 shares, compared to its average volume of 34,664,234. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company's 50 day moving average is $26.09 and its two-hundred day moving average is $27.97. The company has a market capitalization of $147.40 billion, a price-to-earnings ratio of 35.15, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. Equities research analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.